Central Institutional Review Board (CIRB)
The NCI Central Institutional Review Board is dedicated to protecting the rights and welfare of participants in cancer clinical trials. Institutions across the country rely on our national experts to ensure that clinical trials are reviewed efficiently and with the highest ethical and quality standards. We play a critical role in helping the National Cancer Institute accelerate scientific discovery and improve cancer prevention, treatment and care.
The CIRB provides review of protocols submitted by these Networks to ensure the safety of all participants in the trial. The current list of supported Networks includes:
• NCI National Clinical Trials Network (NCTN)
• NCI Experimental Therapeutics Clinical Trials Network (ETCTN)
• NCI Community Oncology Research Program (NCORP)
• Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)
The CIRB supports more than 1,800 institutions, such as hospitals and universities, conducting clinical studies aimed at preventing and treating cancer.